VIROPHARMA INC (VPHM)

Overview Price 30.65 Price Change Today 0.00 (0.00%) P&P rating Zacks Rank 1 - STRONG BUY Open Price $0.00 Previous Close $30.65 Daily Range $0.00 - $0.00 52-Week Range $14.62 - $31.00 Volume 0 ViroPharma Incorporated is an international biopharmaceutical company focused on developing and commercializing products for physician specialists or in hospital settings. The Company's marketed products include Cinryze TM and Vancocin?. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema (HAE), also known as C1 inhibitor (C1-INH) deficiency, a rare, severely debilitating, life-threatening genetic disorder. Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI), or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile. The Company sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. ViroPharma Incorporated is headquartered in Exton, Pennsylvania. Other Resources for VPHM Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary Zacks Blog: Update on VPHM's Industrial Facility February 9, 2012 Zacks Blog: Priority Review for VPHM's Drug January 16, 2012 Zacks Blog: Optimer Buoyant on Difficid Sales January 12, 2012 Zacks Blog: Company News for January 9, 2012 January 9, 2012 Zacks Blog: ViroPharma Expects a Strong 2012 January 6, 2012 ViroPharma Incorporated is an international biopharmaceutical company focused on developing and commercializing products for physician specialists or in hospital settings. The Company's marketed products include Cinryze TM and Vancocin?. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema (HAE), also known as C1 inhibitor (C1-INH) deficiency, a rare, severely debilitating, life-threatening genetic disorder. Vancocin is a potent antibiotic to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI), or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile. The Company sells its products directly to wholesale drug distributors, and specialty pharmacies/specialty distributors. ViroPharma Incorporated is headquartered in Exton, Pennsylvania.   Brokerage Analyst Recommendations 15 Brokerage Firms Covering VPHM   Strong Buy 11 Buy 0 Hold 4 Sell 0 Strong Sell 0 Average Broker Recommendation (ABR): 1.53   VPHM Ratings: BUY  SELL  HOLD VPHM Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 118 Buy 1 Sell   Top Buy Analysis BUY: VPHM Company: VIROPHARMA INCORPORATED Points: 330.13 Start Price: $6.19 Start Date: 02/10/2009 3:55 PM JoeThePlumber P&P Score: 99.40 Recs: Outperform. Comments: 0 | Comment More Recent Analysis Top Sell Analysis SELL: VPHM Company: VIROPHARMA INCORPORATED Points: -129.93 Start Price: $12.10 Start Date: 02/25/2010 11:11 AM harish63 P&P Score: 0.54 Recs: Comments: 0 | Comment More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
Zacks_Analysts	0.00	02/09/12	Update on VPHM's Industrial Facility - Analyst Blog	0
Zacks_Analysts	0.00	01/16/12	Priority Review for VPHM's Drug - Analyst Blog	0
Zacks_Analysts	0.00	01/12/12	Optimer Buoyant on Difficid Sales - Analyst Blog	0
Zacks_Analysts	0.00	01/06/12	ViroPharma Expects a Strong 2012 - Analyst Blog	0
Zacks_Analysts	0.00	12/14/11	Optimer's Dificlir Cleared in EU - Analyst Blog	0
Zacks_Analysts	0.00	12/14/11	ViroPharma's Seizure Drug Reaches UK - Analyst Blog	0
Zacks_Analysts	0.00	12/07/11	ViroPharma-Halozyme Drug Advances - Analyst Blog	0
Zacks_Analysts	0.00	12/01/11	Optimer Moved Down to Neutral - Analyst Blog	0
Zacks_Analysts	0.00	11/16/11	ViroPharma Seals DuoCort Purchase - Analyst Blog	0
Zacks_Analysts	0.00	11/15/11	EU Nod for ViroPharma-DuoCort Drug - Analyst Blog	0

Pages: [ 1 ]  2   3   4   5   6  >>

Commentary

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $6.19 Points: +330.13 Created: 02/10/2009 Outperform. Comments: 0 | Comment JoeThePlumber Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $12.87 Points: +85.14 Created: 12/19/2008 Low PEG, beating estimates, estimates revised upwards, high growth rate, decreasing debt to equity and debt to capital. This is a pharmaceutical company. The health care sector is typically not affected as much as other sectors of the economy during economic downturns. Comments: 0 | Comment DemonSeed Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $11.98 Points: +149.76 Created: 07/30/2008 Good Q2 earnings Comments: 0 | Comment LeveneOMurray Recs:

SELL: VIROPHARMA INCORPORATED (VPHM) Start Price: $12.10 Points: -129.93 Created: 02/25/2010 Comments: 0 | Comment harish63 Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $5.31 Points: +414.89 Created: 04/03/2009 do it Comments: 0 | Comment f1ndforty Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $13.83 Points: +115.11 Created: 08/21/2008 Comments: 0 | Comment deviljix Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $11.72 Points: +154.54 Created: 07/08/2008 Comments: 0 | Comment SP500 Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $7.94 Points: +291.36 Created: 01/01/2008 Comments: 0 | Comment beamco Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $7.94 Points: +291.36 Created: 01/01/2008 Comments: 0 | Comment Duff Recs:

BUY: VIROPHARMA INCORPORATED (VPHM) Start Price: $7.94 Points: +291.36 Created: 01/01/2008 Comments: 0 | Comment mrpid Recs:

Pages: [ 1 ]  2   3   4   5   ...  12  >>

Picks

Username	P&P Score	Call	Time Frame	Start Date	Start Price	Today (change)	Stock Gain	S&P Gain	Points	Analysis
harish63	0.54	SELL	Three Plus Years	02/25/2010	$12.10	$30.55 (+0.96%)	+152.48%	+22.55%	-129.93
f1ndforty	99.65	BUY	Six Months to a Year	04/03/2009	$5.31	$30.55 (+0.96%)	+475.33%	+60.44%	+414.89	view close
JoeThePlumber	99.40	BUY	One to Three Months	02/10/2009	$6.19	$30.55 (+0.96%)	+393.54%	+63.41%	+330.13	view close
DemonSeed	85.84	BUY	Six Months to a Year	12/19/2008	$12.87	$30.55 (+0.96%)	+137.37%	+52.24%	+85.14	view close
deviljix	60.96	BUY	Six Months to a Year	08/21/2008	$13.83	$30.55 (+0.96%)	+120.90%	+5.79%	+115.11
LeveneOMurray	0.45	BUY	Week or Less	07/30/2008	$11.98	$30.55 (+0.96%)	+155.01%	+5.25%	+149.76	view close
SP500	32.68	BUY	Three to Six Months	07/08/2008	$11.72	$30.55 (+0.96%)	+160.67%	+6.12%	+154.54
beamco	27.37	BUY	Six Months to a Year	01/01/2008	$7.94	$30.55 (+0.96%)	+284.76%	-6.60%	+291.36
Duff		BUY	Six Months to a Year	01/01/2008	$7.94	$30.55 (+0.96%)	+284.76%	-6.60%	+291.36
mrpid	72.43	BUY	Six Months to a Year	01/01/2008	$7.94	$30.55 (+0.96%)	+284.76%	-6.60%	+291.36

Pages: [ 1 ]  2   3   4   5   ...  12  >>